Skip to main content

Advertisement

Log in

Phase II study of safety and efficacy of BEB (bendamustine, etoposide, and busulfan) conditioning regimen for autologous stem cell transplantation in non-Hodgkin lymphoma

Annals of Hematology Aims and scope Submit manuscript

Abstract

Autologous stem cell transplant (ASCT) is an effective treatment for non-Hodgkin lymphoma (NHL). However, recent supply issues and toxicity of carmustine have necessitated a new conditioning regimen. We conducted a multicenter, phase II study of BEB (busulfan, etoposide, and bendamustine) conditioning regimen for ASCT in patients with NHL. Thirty-one patients were enrolled and underwent ASCT with the BEB conditioning regimen. The most common subtype was diffuse large B-cell lymphoma (n = 23, 74.2%). Nine patients (29.0%) had a history of relapse, and 18 patients (58.1%) received more than 2 lines of chemotherapy before ASCT. A median number of 6.05 × 106/kg CD34 cells were infused, and all patients engrafted after a median period of 11 days. Thirteen patients (41.9%) experienced neutropenic fever, and 16 patients (51.6%) had grade 3 or 4 toxicities during ASCT. No one had a documented infection, veno-occlusive disease, or treatment-related death. Three-month complete remission rate was 81.8%. Median follow-up period of 15 months showed 6 patients (19.4%) relapsed or progressed and 3 patients died. The estimated 2-year progression-free survival and overall survival rate were 73.0% and 89.8%, respectively. Our results show that BEB conditioning regimens for ASCT are feasible with tolerable toxicity in patients with NHL.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2

Similar content being viewed by others

References

  1. Smeland KB, Kiserud CE, Lauritzsen GF, Fagerli U-M, Falk RS, Fluge Ø, Fosså A, Kolstad A, Loge JH, Maisenhölder M, Kvaløy S, Holte H (2015) Conditional survival and excess mortality after high-dose therapy with autologous stem cell transplantation for adult refractory or relapsed Hodgkin lymphoma in Norway. Haematologica 100(6):e240–e243. https://doi.org/10.3324/haematol.2014.119214

    Article  PubMed  PubMed Central  Google Scholar 

  2. Moskowitz AJ, Moskowitz CH (2009) Controversies in the treatment of lymphoma with autologous transplantation. Oncologist 14(9):921–929. https://doi.org/10.1634/theoncologist.2009-0162

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  3. Stiff PJ, Unger JM, Cook JR, Constine LS, Couban S, Stewart DA, Shea TC, Porcu P, Winter JN, Kahl BS, Miller TP, Tubbs RR, Marcellus D, Friedberg JW, Barton KP, Mills GM, LeBlanc M, Rimsza LM, Forman SJ, Fisher RI (2013) Autologous transplantation as consolidation for aggressive non-Hodgkin's lymphoma. N Engl J Med 369(18):1681–1690. https://doi.org/10.1056/NEJMoa1301077

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  4. Cortelazzo S, Tarella C, Gianni AM, Ladetto M, Barbui AM, Rossi A, Gritti G, Corradini P, Di Nicola M, Patti C, Mule A, Zanni M, Zoli V, Billio A, Piccin A, Negri G, Castellino C, Di Raimondo F, Ferreri AJ, Benedetti F, La Nasa G, Gini G, Trentin L, Frezzato M, Flenghi L, Falorio S, Chilosi M, Bruna R, Tabanelli V, Pileri S, Masciulli A, Delaini F, Boschini C, Rambaldi A (2016) Randomized trial comparing R-CHOP versus high-dose sequential chemotherapy in high-risk patients with diffuse large B-cell lymphomas. J Clin Oncol 34(33):4015–4022. https://doi.org/10.1200/jco.2016.67.2980

    Article  CAS  PubMed  Google Scholar 

  5. Pettengell R, Radford JA, Morgenstern GR, Scarffe JH, Harris M, Woll PJ, Deakin DP, Ryder D, Wilkinson PM, Crowther D (1996) Survival benefit from high-dose therapy with autologous blood progenitor-cell transplantation in poor-prognosis non-Hodgkin's lymphoma. J Clin Oncol 14(2):586–592. https://doi.org/10.1200/jco.1996.14.2.586

    Article  CAS  PubMed  Google Scholar 

  6. Milpied N, Deconinck E, Gaillard F, Delwail V, Foussard C, Berthou C, Gressin R, Lucas V, Colombat P, Harousseau JL (2004) Initial treatment of aggressive lymphoma with high-dose chemotherapy and autologous stem-cell support. N Engl J Med 350(13):1287–1295. https://doi.org/10.1056/NEJMoa031770

    Article  CAS  PubMed  Google Scholar 

  7. Mills W, Chopra R, McMillan A, Pearce R, Linch DC, Goldstone AH (1995) BEAM chemotherapy and autologous bone marrow transplantation for patients with relapsed or refractory non-Hodgkin's lymphoma. J Clin Oncol 13(3):588–595. https://doi.org/10.1200/jco.1995.13.3.588

    Article  CAS  PubMed  Google Scholar 

  8. Philip T, Chauvin F, Armitage J, Bron D, Hagenbeek A, Biron P, Spitzer G, Velasquez W, Weisenburger DD, Fernandez-Ranada J et al (1991) Parma international protocol: pilot study of DHAP followed by involved-field radiotherapy and BEAC with autologous bone marrow transplantation. Blood 77(7):1587–1592

    Article  CAS  Google Scholar 

  9. Aggarwal C, Gupta S, Vaughan WP, Saylors GB, Salzman DE, Katz RO, Nance AG, Tilden AB, Carabasi MH (2006) Improved outcomes in intermediate- and high-risk aggressive non-Hodgkin lymphoma after autologous hematopoietic stem cell transplantation substituting intravenous for oral busulfan in a busulfan, cyclophosphamide, and etoposide preparative regimen. Biol Blood Marrow Transplant 12(7):770–777. https://doi.org/10.1016/j.bbmt.2006.03.016

    Article  CAS  PubMed  Google Scholar 

  10. Copelan EA, Penza SL, Pohlman B, Avalos BR, Goormastic M, Andresen SW, Kalaycio M, Bechtel TP, Scholl MD, Elder PJ, Ezzone SA, O'Donnell LC, Tighe MB, Risley GL, Young DC, Bolwell BJ (2000) Autotransplantation following busulfan, etoposide and cyclophosphamide in patients with non-Hodgkin's lymphoma. Bone Marrow Transplant 25:1243–1248. https://doi.org/10.1038/sj.bmt.1702433

    Article  CAS  PubMed  Google Scholar 

  11. Escalón MP, Stefanovic A, Venkatraman A, Pereira D, Santos ES, Goodman M, Byrnes JJ, Fernandez HF (2009) Autologous transplantation for relapsed non-Hodgkin's lymphoma using intravenous busulfan and cyclophosphamide as conditioning regimen: a single center experience. Bone Marrow Transplant 44:89–96. https://doi.org/10.1038/bmt.2008.429

    Article  CAS  PubMed  Google Scholar 

  12. Hänel M, Kröger N, Sonnenberg S, Bornhäuser M, Krüger W, Kroschinsky F, Hänel A, Metzner B, Birkmann J, Schmid B, Hoffknecht M, Fiedler F, Ehninger G, Zander A (2002) Busulfan, cyclophosphamide, and etoposide as high-dose conditioning regimen in patients with malignant lymphoma. Ann Hematol 81(2):96–102. https://doi.org/10.1007/s00277-001-0413-8

    Article  CAS  PubMed  Google Scholar 

  13. Kim JG, Sohn SK, Chae YS, Yang DH, Lee JJ, Kim HJ, Shin HJ, Jung JS, Kim WS, Kim DH, Suh C, Kim SJ, Eom HS, Bae SH (2007) Multicenter study of intravenous busulfan, cyclophosphamide, and etoposide (i.v. Bu/Cy/E) as conditioning regimen for autologous stem cell transplantation in patients with non-Hodgkin’s lymphoma. Bone Marrow Transplant 40:919–924. https://doi.org/10.1038/sj.bmt.1705841

    Article  CAS  PubMed  Google Scholar 

  14. Kim JE, Lee DH, Yoo C, Kim S, Kim S-W, Lee J-S, Park CJ, Huh J, Suh C (2011) BEAM or BuCyE high-dose chemotherapy followed by autologous stem cell transplantation in non-Hodgkin's lymphoma patients: a single center comparative analysis of efficacy and toxicity. Leuk Res 35(2):183–187. https://doi.org/10.1016/j.leukres.2010.07.016

    Article  CAS  PubMed  Google Scholar 

  15. Kröger N, Hoffknecht M, Dreger P, Krüger W, Zeller W, Krüll A, Stockschläder M, Bittner S, Weh HJ, Zander AR (1998) Long-term disease-free survival of patients with advanced mantle-cell lymphoma following high-dose chemotherapy. Bone Marrow Transplant 21:55–57. https://doi.org/10.1038/sj.bmt.1701033

    Article  PubMed  Google Scholar 

  16. Williams CB, Day SD, Reed MD, Copelan EA, Bechtel T, Leather HL, Wingard JR, Abbott BL, Abhyankar S, McGuirk JP (2004) Dose modification protocol using intravenous busulfan (Busulfex) and cyclophosphamide followed by autologous or allogeneic peripheral blood stem cell transplantation in patients with hematologic malignancies. Biol Blood Marrow Transplant 10(9):614–623. https://doi.org/10.1016/j.bbmt.2004.05.010

    Article  CAS  PubMed  Google Scholar 

  17. Zhang H, Graiser M, Hutcherson DA, Dada MO, McMillan S, Ali Z, Flowers CR, Waller EK (2012) Pharmacokinetic-directed high-dose busulfan combined with cyclophosphamide and etoposide results in predictable drug levels and durable long-term survival in lymphoma patients undergoing autologous stem cell transplantation. Biol Blood Marrow Transplant 18(8):1287–1294. https://doi.org/10.1016/j.bbmt.2012.02.006

    Article  CAS  PubMed  Google Scholar 

  18. Ciurea SO, Andersson BS (2009) Busulfan in hematopoietic stem cell transplantation. Biol Blood Marrow Transplant 15(5):523–536. https://doi.org/10.1016/j.bbmt.2008.12.489

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  19. Leoni LM, Bailey B, Reifert J, Bendall HH, Zeller RW, Corbeil J, Elliott G, Niemeyer CC (2008) Bendamustine (Treanda) displays a distinct pattern of cytotoxicity and unique mechanistic features compared with other alkylating agents. Clin Cancer Res 14(1):309–317. https://doi.org/10.1158/1078-0432.Ccr-07-1061

    Article  CAS  PubMed  Google Scholar 

  20. Darwish M, Bond M, Hellriegel E, Robertson P Jr, Chovan JP (2015) Pharmacokinetic and pharmacodynamic profile of bendamustine and its metabolites. Cancer Chemother Pharmacol 75(6):1143–1154. https://doi.org/10.1007/s00280-015-2727-6

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  21. Cheson BD, Pfistner B, Juweid ME, Gascoyne RD, Specht L, Horning SJ, Coiffier B, Fisher RI, Hagenbeek A, Zucca E, Rosen ST, Stroobants S, Lister TA, Hoppe RT, Dreyling M, Tobinai K, Vose JM, Connors JM, Federico M, Diehl V (2007) Revised response criteria for malignant lymphoma. J Clin Oncol 25(5):579–586. https://doi.org/10.1200/jco.2006.09.2403

    Article  PubMed  Google Scholar 

  22. Schmitz N, Pfistner B, Sextro M, Sieber M, Carella AM, Haenel M, Boissevain F, Zschaber R, Muller P, Kirchner H, Lohri A, Decker S, Koch B, Hasenclever D, Goldstone AH, Diehl V (2002) Aggressive conventional chemotherapy compared with high-dose chemotherapy with autologous haemopoietic stem-cell transplantation for relapsed chemosensitive Hodgkin's disease: a randomised trial. Lancet 359(9323):2065–2071. https://doi.org/10.1016/s0140-6736(02)08938-9

    Article  CAS  PubMed  Google Scholar 

  23. Philip T, Armitage JO, Spitzer G, Chauvin F, Jagannath S, Cahn JY, Colombat P, Goldstone AH, Gorin NC, Flesh M et al (1987) High-dose therapy and autologous bone marrow transplantation after failure of conventional chemotherapy in adults with intermediate-grade or high-grade non-Hodgkin's lymphoma. N Engl J Med 316(24):1493–1498. https://doi.org/10.1056/nejm198706113162401

    Article  CAS  PubMed  Google Scholar 

  24. Philip T, Guglielmi C, Hagenbeek A, Somers R, Van der Lelie H, Bron D, Sonneveld P, Gisselbrecht C, Cahn JY, Harousseau JL et al (1995) Autologous bone marrow transplantation as compared with salvage chemotherapy in relapses of chemotherapy-sensitive non-Hodgkin's lymphoma. N Engl J Med 333(23):1540–1545. https://doi.org/10.1056/nejm199512073332305

    Article  CAS  PubMed  Google Scholar 

  25. van Besien K, Tabocoff J, Rodriguez M, Andersson B, Mehra R, Przepiorka D, Dimopoulos M, Giralt S, Suki S, Khouri I et al (1995) High-dose chemotherapy with BEAC regimen and autologous bone marrow transplantation for intermediate grade and immunoblastic lymphoma: durable complete remissions, but a high rate of regimen-related toxicity. Bone Marrow Transplant 15(4):549–555

    PubMed  Google Scholar 

  26. Gribben JG, Linch DC, Singer CR, McMillan AK, Jarrett M, Goldstone AH (1989) Successful treatment of refractory Hodgkin's disease by high-dose combination chemotherapy and autologous bone marrow transplantation. Blood 73(1):340–344

    Article  CAS  Google Scholar 

  27. Jo JC, Kang BW, Jang G, Sym SJ, Lee SS, Koo JE, Kim JW, Kim S, Huh J, Suh C (2008) BEAC or BEAM high-dose chemotherapy followed by autologous stem cell transplantation in non-Hodgkin's lymphoma patients: comparative analysis of efficacy and toxicity. Ann Hematol 87(1):43–48. https://doi.org/10.1007/s00277-007-0360-0

    Article  CAS  PubMed  Google Scholar 

  28. Salar A, Sierra J, Gandarillas M, Caballero MD, Marin J, Lahuerta JJ, Garcia-Conde J, Arranz R, Leon A, Zuazu J, Garcia-Larana J, Lopez-Guillermo A, Sanz MA, Granena A, Garcia JC, Conde E (2001) Autologous stem cell transplantation for clinically aggressive non-Hodgkin's lymphoma: the role of preparative regimens. Bone Marrow Transplant 27(4):405–412. https://doi.org/10.1038/sj.bmt.1702795

    Article  CAS  PubMed  Google Scholar 

  29. Mills W, Strang J, Goldstone AH, Linch DC (1995) Dose intensification of etoposide in the BEAM ABMT protocol for malignant lymphoma. Leuk Lymphoma 17(3–4):263–270. https://doi.org/10.3109/10428199509056831

    Article  CAS  PubMed  Google Scholar 

  30. Bhatia S, Robison LL, Francisco L, Carter A, Liu Y, Grant M, Baker KS, Fung H, Gurney JG, McGlave PB, Nademanee A, Ramsay NK, Stein A, Weisdorf DJ, Forman SJ (2005) Late mortality in survivors of autologous hematopoietic-cell transplantation: report from the bone marrow transplant survivor study. Blood 105(11):4215–4222. https://doi.org/10.1182/blood-2005-01-0035

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  31. Isidori A, Christofides A, Visani G (2016) Novel regimens prior to autologous stem cell transplantation for the management of adults with relapsed/refractory non-Hodgkin lymphoma and Hodgkin lymphoma: alternatives to BEAM conditioning. Leuk Lymphoma 57(11):2499–2509. https://doi.org/10.1080/10428194.2016.1185785

    Article  CAS  PubMed  Google Scholar 

  32. Visani G, Malerba L, Stefani PM, Capria S, Galieni P, Gaudio F, Specchia G, Meloni G, Gherlinzoni F, Giardini C, Falcioni S, Cuberli F, Gobbi M, Sarina B, Santoro A, Ferrara F, Rocchi M, Ocio EM, Caballero MD, Isidori A (2011) BeEAM (bendamustine, etoposide, cytarabine, melphalan) before autologous stem cell transplantation is safe and effective for resistant/relapsed lymphoma patients. Blood 118(12):3419–3425. https://doi.org/10.1182/blood-2011-04-351924

    Article  CAS  PubMed  Google Scholar 

  33. Copelan EA, Kapoor N, Gibbins B, Tutschka PJ (1990) Allogeneic marrow transplantation in non-Hodgkin's lymphoma. Bone Marrow Transplant 5(1):47–50

    CAS  PubMed  Google Scholar 

  34. Dean RM, Pohlman B, Sweetenham JW, Sobecks RM, Kalaycio ME, Smith SD, Copelan EA, Andresen S, Rybicki LA, Curtis J, Bolwell BJ (2010) Superior survival after replacing oral with intravenous busulfan in autologous stem cell transplantation for non-Hodgkin lymphoma with busulfan, cyclophosphamide and etoposide. Br J Haematol 148(2):226–234. https://doi.org/10.1111/j.1365-2141.2009.07940.x

    Article  CAS  PubMed  Google Scholar 

  35. Andion M, Molina B, Gonzalez-Vicent M, Alonso L, Hernandez C, Lassaletta A, Lopez-Ibor B, Villa M, Diaz MA (2011) High-dose busulfan and cyclophosphamide as a conditioning regimen for autologous peripheral blood stem cell transplantation in childhood non-Hodgkin lymphoma patients: a long-term follow-up study. J Pediatr Hematol Oncol 33(3):e89–e91. https://doi.org/10.1097/MPH.0b013e3181fd6c79

    Article  CAS  PubMed  Google Scholar 

  36. Shin HJ, Lee WS, Lee HS, Kim H, Lee GW, Song MK, Kim JS, Yhim HY, Chung JS (2014) Busulfan-containing conditioning regimens are optimal preparative regimens for autologous stem cell transplant in patients with diffuse large B-cell lymphoma. Leuk Lymphoma 55(11):2490–2496. https://doi.org/10.3109/10428194.2014.882504

    Article  CAS  PubMed  Google Scholar 

  37. Wang EH, Chen YA, Corringham S, Bashey A, Holman P, Ball ED, Carrier E (2004) High-dose CEB vs BEAM with autologous stem cell transplant in lymphoma. Bone Marrow Transplant 34(7):581–587. https://doi.org/10.1038/sj.bmt.1704637

    Article  CAS  PubMed  Google Scholar 

  38. Sharma A, Kayal S, Iqbal S, Malik PS, Raina V (2013) Comparison of BEAM vs. LEAM regimen in autologous transplant for lymphoma at AIIMS. SpringerPlus 2:489. https://doi.org/10.1186/2193-1801-2-489

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  39. Lucijanic M, Prka Z, Jaksic O, Mitrovic Z, Vrkljan A, Pejsa V (2019) Bendamustine-based conditioning prior to autologous stem cell transplantation is associated with high rate of febrile neutropenia and higher mortality. Am J Hematol 94(2):E42–e43. https://doi.org/10.1002/ajh.25340

    Article  PubMed  Google Scholar 

  40. Redondo AM, Valcarcel D, Gonzalez-Rodriguez AP, Suarez-Lledo M, Bello JL, Canales M, Gayoso J, Colorado M, Jarque I, Del Campo R, Arranz R, Terol MJ, Rifon JJ, Rodriguez MJ, Ramirez MJ, Castro N, Sanchez A, Lopez-Jimenez J, Montes-Moreno S, Briones J, Lopez A, Palomera L, Lopez-Guillermo A, Caballero D, Martin A (2018) Bendamustine as part of conditioning of autologous stem cell transplantation in patients with aggressive lymphoma: a phase 2 study from the GELTAMO group. Br J Haematol. https://doi.org/10.1111/bjh.15713

  41. Chantepie SP, Garciaz S, Tchernonog E, Peyrade F, Larcher MV, Diouf M, Fornecker LM, Houot R, Gastinne T, Soussain C, Malak S, Lemal R, Delette C, Ibrahim A, Gac AC, Reboursiere E, Vilque JP, Bekadja MA, Casasnovas RO, Gressin R, Guidez S, Coso D, Herbaux C, Yakoub-Agha I, Bouabdallah K, Durot E, Damaj G (2018) Bendamustine-based conditioning prior to autologous stem cell transplantation (ASCT): results of a French multicenter study of 474 patients from LYmphoma Study Association (LYSA) centers. Am J Hematol 93(6):729–735. https://doi.org/10.1002/ajh.25077

    Article  CAS  PubMed  Google Scholar 

  42. Schmitz N, Nickelsen M, Ziepert M, Haenel M, Borchmann P, Schmidt C, Viardot A, Bentz M, Peter N, Ehninger G, Doelken G, Ruebe C, Truemper L, Rosenwald A, Pfreundschuh M, Loeffler M, Glass B (2012) Conventional chemotherapy (CHOEP-14) with rituximab or high-dose chemotherapy (MegaCHOEP) with rituximab for young, high-risk patients with aggressive B-cell lymphoma: an open-label, randomised, phase 3 trial (DSHNHL 2002-1). Lancet Oncol 13(12):1250–1259. https://doi.org/10.1016/s1470-2045(12)70481-3

    Article  CAS  PubMed  Google Scholar 

Download references

Acknowledgments

We are grateful to the doctors of the multi-centers for collecting and analyzing clinical data.

Author information

Authors and Affiliations

Authors

Corresponding author

Correspondence to Ho-Jin Shin.

Ethics declarations

Conflict of interests

All authors declare that they have no conflict of interest.

Ethical approval

All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and/or national research committee and with the 1964 Helsinki declaration and its later amendments or comparable ethical standards.

Informed consent

Informed consent was obtained from all individual participants included in the study.

Additional information

Publisher’s note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Kim, D.Y., Chung, Js., Jo, JC. et al. Phase II study of safety and efficacy of BEB (bendamustine, etoposide, and busulfan) conditioning regimen for autologous stem cell transplantation in non-Hodgkin lymphoma. Ann Hematol 99, 819–828 (2020). https://doi.org/10.1007/s00277-020-03942-6

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00277-020-03942-6

Keywords

Navigation